A possible explanation is that in patients bearing this haplotype in homozygosis, the levels of TGF‐β1 synthesized, known to affect tumour progression, could be lower than in individuals with the alternative haplotype, who are thus protected against the progression of the tumour. The gene discussed is TGFB1; the disease is neoplasm.